

RECEIVED

APR 0 2 11 13



RECEIVED 03/31/2003

1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/909,164

DATE: 03/31/2003

TIME: 09:34:26

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

3 <110> APPLICANT: Corvas International, Inc.
 4 Lim-Wilby, Marguerita
 5 Levy, Odile E
 6 Brunck, Terence K
 8 <120> TITLE OF INVENTION: NOVEL PEPTIDES AS NS-3-SERINE PROTEASE INHIBITORS OF
 HEPATITIS C VIRUS
 10 <130> FILE REFERENCE: IN01192-US
 12 <140> CURRENT APPLICATION NUMBER: 09/909,164
 C--> 13 <141> **CURRENT FILING DATE: 2003-03-25**
 15 <150> PRIOR APPLICATION NUMBER: 60/220,101
 16 <151> PRIOR FILING DATE: 2000-07-21
 18 <160> NUMBER OF SEQ ID NOS: 62
 20 <170> SOFTWARE: PatentIn version 3.1
 22 <210> SEQ ID NO: 1
 23 <211> LENGTH: 8
 24 <212> TYPE: PRT
 25 <213> ORGANISM: Artificial Sequence
 27 <220> FEATURE:
 28 <223> OTHER INFORMATION: substrate peptide
 30 <220> FEATURE:
 31 <221> NAME/KEY: MOD_RES
 32 <222> LOCATION: (1)..(1)
 33 <223> OTHER INFORMATION: ACETYLATION
 36 <220> FEATURE:
 37 <221> NAME/KEY: MISC_FEATURE
 38 <223> OTHER INFORMATION: substrate peptide
 41 <220> FEATURE:
 42 <221> NAME/KEY: MISC_FEATURE
 43 <222> LOCATION: (7)..(7)
 44 <223> OTHER INFORMATION: Alanine or Proline
 47 <220> FEATURE:
 48 <221> NAME/KEY: MISC_FEATURE
 49 <222> LOCATION: (8)..(8)
 50 <223> OTHER INFORMATION: Norvaline
 53 <400> SEQUENCE: 1
 W--> 55 Asp Thr Glu Asp Val Val Xaa Xaa
 56 1 5
 59 <210> SEQ ID NO: 2
 60 <211> LENGTH: 6
 61 <212> TYPE: PRT
 62 <213> ORGANISM: Artificial Sequence
 64 <220> FEATURE:
 65 <223> OTHER INFORMATION: competitive inhibitor peptide
 67 <220> FEATURE:

pp 6-7

ENTERED

RAW SEQUENCE LISTING

DATE: 03/31/2003

PATENT APPLICATION: US/09/909,164

TIME: 09:34:26

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

68 <221> NAME/KEY: MISC_FEATURE
69 <222> LOCATION: (2)..(2) //
70 <223> OTHER INFORMATION: gamma-carboxyglutamic acid (D-Gla)
73 <220> FEATURE:
74 <221> NAME/KEY: MISC_FEATURE
75 <222> LOCATION: (5)..(5) /
76 <223> OTHER INFORMATION: cyclohexyl alanine
79 <220> FEATURE:
80 <221> NAME/KEY: MOD_RES
81 <222> LOCATION: (1)..(1)
82 <223> OTHER INFORMATION: ACETYLATION
85 <400> SEQUENCE: 2
W--> 87 Asp Xaa Leu Ile Xaa Cys
88 1 5
91 <210> SEQ ID NO: 3
92 <211> LENGTH: 8
93 <212> TYPE: PRT
94 <213> ORGANISM: Artificial Sequence
96 <220> FEATURE:
97 <223> OTHER INFORMATION: competitive inhibitor peptide
99 <220> FEATURE:
100 <221> NAME/KEY: MOD_RES
101 <222> LOCATION: (1)..(1)
102 <223> OTHER INFORMATION: ACETYLATION
105 <220> FEATURE:
106 <221> NAME/KEY: MISC_FEATURE
107 <222> LOCATION: (8)..(8) /
108 <223> OTHER INFORMATION: norvaline
111 <400> SEQUENCE: 3
W--> 113 Asp Thr Glu Asp Val Val Ala Xaa
114 1 5
117 <210> SEQ ID NO: 4
118 <211> LENGTH: 8
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
123 <223> OTHER INFORMATION: competitive inhibitor peptide
125 <220> FEATURE:
126 <221> NAME/KEY: MOD_RES
127 <222> LOCATION: (1)..(1)
128 <223> OTHER INFORMATION: ACETYLATION
131 <220> FEATURE:
132 <221> NAME/KEY: MISC_FEATURE
133 <222> LOCATION: (8)..(8) /
134 <223> OTHER INFORMATION: norvaline
137 <400> SEQUENCE: 4
W--> 139 Asp Thr Glu Asp Val Val Pro Xaa
140 1 5
143 <210> SEQ ID NO: 5

RAW SEQUENCE LISTING

DATE: 03/31/2003

PATENT APPLICATION: US/09/909,164

TIME: 09:34:26

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

144 <211> LENGTH: 11
 145 <212> TYPE: PRT
 146 <213> ORGANISM: artificial sequence
 148 <220> FEATURE:
 149 <223> OTHER INFORMATION: 11-mer synthesized according to example 1
 151 <220> FEATURE:
 152 <221> NAME/KEY: MOD_RES
 153 <222> LOCATION: (1)..(1)
 154 <223> OTHER INFORMATION: ACETYLTATION
 157 <220> FEATURE:
 158 <221> NAME/KEY: MISC_FEATURE
 159 <222> LOCATION: (6)..(6)
 160 <223> OTHER INFORMATION: norvaline-(CO)
 163 <220> FEATURE:
 164 <221> NAME/KEY: MOD_RES
 165 <222> LOCATION: (11)..(11)
 166 <223> OTHER INFORMATION: AMIDATION
 169 <400> SEQUENCE: 5

W--> 171 Glu Glu Val Val Pro Xaa Gly Met Ser Tyr Ser

172 1 5 10

175 <210> SEQ ID NO: 6

176 <211> LENGTH: 11

177 <212> TYPE: PRT

178 <213> ORGANISM: artificial sequence

180 <220> FEATURE:

181 <223> OTHER INFORMATION: 11-mer synthesized according to example 1

183 <220> FEATURE:

184 <221> NAME/KEY: MOD_RES

185 <222> LOCATION: (1)..(1)

186 <223> OTHER INFORMATION: ACETYLTATION

189 <220> FEATURE:

190 <221> NAME/KEY: MISC_FEATURE

191 <222> LOCATION: (6)..(6)

192 <223> OTHER INFORMATION: norvaline-(CO)

195 <220> FEATURE:

196 <221> NAME/KEY: MISC_FEATURE

197 <222> LOCATION: (9)..(9)

198 <223> OTHER INFORMATION: D-amino acid

201 <220> FEATURE:

202 <221> NAME/KEY: MOD_RES

203 <222> LOCATION: (11)..(11)

204 <223> OTHER INFORMATION: AMIDATION

207 <400> SEQUENCE: 6

W--> 209 Glu Glu Val Val Pro Xaa Gly Met Ser Tyr Ser

210 1 5 10

213 <210> SEQ ID NO: 7

214 <211> LENGTH: 11

215 <212> TYPE: PRT

216 <213> ORGANISM: artificial sequence

RAW SEQUENCE LISTING

DATE: 03/31/2003

PATENT APPLICATION: US/09/909,164

TIME: 09:34:26

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

218 <220> FEATURE:
 219 <223> OTHER INFORMATION: 11-mer synthesized according to example 1
 221 <220> FEATURE:
 222 <221> NAME/KEY: MOD_RES
 223 <222> LOCATION: (1)..(1)
 224 <223> OTHER INFORMATION: ACETYLTATION
 227 <220> FEATURE:
 228 <221> NAME/KEY: MISC_FEATURE
 229 <222> LOCATION: (6)..(6)
 230 <223> OTHER INFORMATION: norvaline-(CO)
 233 <220> FEATURE:
 234 <221> NAME/KEY: MISC_FEATURE
 235 <222> LOCATION: (9)..(9)
 236 <223> OTHER INFORMATION: D-amino acid
 239 <220> FEATURE:
 240 <221> NAME/KEY: MOD_RES
 241 <222> LOCATION: (11)..(11)
 242 <223> OTHER INFORMATION: AMIDATION
 245 <400> SEQUENCE: 7

W--> 247 Glu Glu Val Val Pro Xaa Gly Met His Tyr Ser

248 1 5 10

251 <210> SEQ ID NO: 8

252 <211> LENGTH: 11

253 <212> TYPE: PRT

254 <213> ORGANISM: artificial sequence

256 <220> FEATURE:

257 <223> OTHER INFORMATION: 11-mer synthesized according to example 1

259 <220> FEATURE:

260 <221> NAME/KEY: MOD_RES

261 <222> LOCATION: (1)..(1)

262 <223> OTHER INFORMATION: ACETYLTATION

265 <220> FEATURE:

266 <221> NAME/KEY: MISC_FEATURE

267 <222> LOCATION: (6)..(6)

268 <223> OTHER INFORMATION: norvaline-(CO)

271 <220> FEATURE:

272 <221> NAME/KEY: MISC_FEATURE

273 <222> LOCATION: (9)..(9)

274 <223> OTHER INFORMATION: D-amino acid

277 <220> FEATURE:

278 <221> NAME/KEY: MOD_RES

279 <222> LOCATION: (11)..(11)

280 <223> OTHER INFORMATION: AMIDATION

283 <400> SEQUENCE: 8

W--> 285 Glu Glu Val Val Pro Xaa Gly Met Asp Tyr Ser

286 1 5 10

289 <210> SEQ ID NO: 9

290 <211> LENGTH: 11

291 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 03/31/2003

PATENT APPLICATION: US/09/909,164

TIME: 09:34:26

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

292 <213> ORGANISM: artificial sequence
294 <220> FEATURE:
295 <223> OTHER INFORMATION: 11-mer synthesized according to example 1
297 <220> FEATURE:
298 <221> NAME/KEY: MOD_RES
299 <222> LOCATION: (1)..(1)
300 <223> OTHER INFORMATION: ACETYLTATION
303 <220> FEATURE:
304 <221> NAME/KEY: MOD_RES
305 <222> LOCATION: (11)..(11)
306 <223> OTHER INFORMATION: AMIDATION
309 <220> FEATURE:
310 <221> NAME/KEY: MISC_FEATURE
311 <222> LOCATION: (6)..(6)
312 <223> OTHER INFORMATION: norvaline-(CO)
315 <220> FEATURE:
316 <221> NAME/KEY: MISC_FEATURE
317 <222> LOCATION: (8)..(8)
318 <223> OTHER INFORMATION: D-amino acid
321 <400> SEQUENCE: 9

W--> 323 Glu Glu Val Val Pro Xaa Gly Met Ser Tyr Ser

324 1 5 10

327 <210> SEQ ID NO: 10

328 <211> LENGTH: 11

329 <212> TYPE: PRT

330 <213> ORGANISM: artificial sequence

332 <220> FEATURE:

333 <223> OTHER INFORMATION: 11-mer synthesized according to example 1

335 <220> FEATURE:

336 <221> NAME/KEY: MOD_RES

337 <222> LOCATION: (1)..(1)

338 <223> OTHER INFORMATION: ACETYLTATION

341 <220> FEATURE:

342 <221> NAME/KEY: MOD_RES

343 <222> LOCATION: (11)..(11)

344 <223> OTHER INFORMATION: AMIDATION

347 <220> FEATURE:

348 <221> NAME/KEY: MISC_FEATURE

349 <222> LOCATION: (6)..(6)

350 <223> OTHER INFORMATION: norvaline-(CO)

353 <220> FEATURE:

354 <221> NAME/KEY: MISC_FEATURE

355 <222> LOCATION: (8)..(9)

356 <223> OTHER INFORMATION: D-amino acids

359 <400> SEQUENCE: 10

W--> 361 Glu Glu Val Val Pro Xaa Gly Met Ser Tyr Ser

362 1 5 10

365 <210> SEQ ID NO: 11

366 <211> LENGTH: 11

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/909,164

DATE: 03/31/2003

TIME: 09:34:27

Input Set : A:\seqlist.txt
Output Set: N:\CRF4\03312003\I909164.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 7, 8
Seq#:2; Xaa Pos. 2, 5
Seq#:3; Xaa Pos. 8
Seq#:4; Xaa Pos. 8
Seq#:5; Xaa Pos. 6
Seq#:6; Xaa Pos. 6
Seq#:7; Xaa Pos. 6
Seq#:8; Xaa Pos. 6
Seq#:9; Xaa Pos. 6
Seq#:10; Xaa Pos. 6
Seq#:11; Xaa Pos. 6
Seq#:12; Xaa Pos. 6
Seq#:13; Xaa Pos. 6
Seq#:14; Xaa Pos. 6
Seq#:15; Xaa Pos. 6
Seq#:16; Xaa Pos. 6
Seq#:17; Xaa Pos. 6
Seq#:18; Xaa Pos. 6
Seq#:19; Xaa Pos. 6
Seq#:20; Xaa Pos. 6
Seq#:21; Xaa Pos. 6
Seq#:22; Xaa Pos. 6
Seq#:23; Xaa Pos. 6
Seq#:24; Xaa Pos. 6
Seq#:25; Xaa Pos. 6
Seq#:26; Xaa Pos. 6
Seq#:27; Xaa Pos. 6
Seq#:28; Xaa Pos. 6
Seq#:29; Xaa Pos. 6
Seq#:30; Xaa Pos. 6
Seq#:31; Xaa Pos. 6
Seq#:32; Xaa Pos. 6
Seq#:33; Xaa Pos. 6
Seq#:34; Xaa Pos. 6
Seq#:35; Xaa Pos. 6
Seq#:36; Xaa Pos. 6
Seq#:37; Xaa Pos. 6
Seq#:38; Xaa Pos. 6
Seq#:39; Xaa Pos. 6
Seq#:40; Xaa Pos. 6
Seq#:41; Xaa Pos. 6
Seq#:42; Xaa Pos. 6, 8
Seq#:43; Xaa Pos. 6, 8
Seq#:44; Xaa Pos. 6, 8

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/909,164

DATE: 03/31/2003

TIME: 09:34:27

Input Set : A:\seqlist.txt

Output Set: N:\CRF4\03312003\I909164.raw

Seq#:45; Xaa Pos. 6,8
Seq#:46; Xaa Pos. 6,8
Seq#:47; Xaa Pos. 6
Seq#:48; Xaa Pos. 6
Seq#:49; Xaa Pos. 6
Seq#:50; Xaa Pos. 6
Seq#:51; Xaa Pos. 6